Astria Therapeutics (ATXS) Stock Price, News & Analysis

Company Overview

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $6.20 to $6.59
• 50-Day Range: $5.36 to $7.02
• 52-Week Range: $3.56 to $12.92
• Volume: 76,139 shs
• Average Volume: 353,238 shs
• Market Capitalization: $354.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.00
• Consensus Rating: Buy

Astria Therapeutics Stock Analysis - MarketRank™

Astria Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 518th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Astria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Astria Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astria Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astria Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Astria Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.41% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Astria Therapeutics has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astria Therapeutics does not currently pay a dividend.

Dividend Growth

Astria Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.41% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Astria Therapeutics has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.02

News Sentiment

Astria Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Astria Therapeutics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for ATXS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

7 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Astria Therapeutics is held by insiders.

Percentage Held by Institutions

98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATXS Stock Analysis - Frequently Asked Questions

How have ATXS shares performed this year?

Astria Therapeutics' stock was trading at $8.94 at the beginning of 2025. Since then, ATXS stock has decreased by 28.9% and is now trading at $6.3540.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) issued its quarterly earnings data on Tuesday, August, 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04.

When did Astria Therapeutics' stock split?

Shares of Astria Therapeutics reverse split before market open on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' top institutional investors include Vestal Point Capital LP (8.01%), JPMorgan Chase & Co. (3.01%), Nantahala Capital Management LLC (1.90%) and Geode Capital Management LLC (1.71%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito.
View institutional ownership trends.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Astria Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXS
• CIK: 1454789
• Web: www.catabasis.com
• Phone: (617) 349-1971
• Fax: 617-273-2637
• Employees: 30
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Astria Therapeutics: $29.00
• High Price Target: $47.00
• Low Price Target: $16.00
• Potential Upside/Downside: +344.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.39%
• Return on Assets: -36.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.89
• Quick Ratio: 14.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.93 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 56,440,000
• Free Float: 53,895,000
• Market Cap: $368.55 million
• Optionable: Optionable
• Beta: 0.48